Unión Europea - español - EMA (European Medicines Agency)

biomarin international limited - cerliponasa alfa - neurona ceroide-lipofuscinosis - otros tracto alimentario y metabolismo de los productos, - brineura está indicado para el tratamiento de las neuronas de ceroid lipofuscinosis tipo 2 (cln2) de la enfermedad, también conocida como tripeptidyl peptidasa 1 (tpp1), la deficiencia,.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

tagumedica s.a. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

tagumedica s.a. -

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

viatris limited - simvastatina; ezetimiba - comprimido - 20 mg/10 mg - simvastatina 20 mg; ezetimiba 10 mg - simvastatina y ezetimiba

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

viatris limited - simvastatina; ezetimiba - comprimido - 40 mg/10 mg - simvastatina 40 mg; ezetimiba 10 mg - simvastatina y ezetimiba

Unión Europea - español - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. para obtener más información sobre el estado del receptor 2 del factor de crecimiento epidérmico humano (her2), consulte la sección 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. para más información sobre el estado de her2, consulte la sección 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

recordati ireland limited - alprostadil - excipientes: etanol anhidro,hidroxido de sodio (e-524),dihidrogenofosfato de potasio - otros productos de uso urolÓgico, incluyendo antiespasmÓdicos - fármacos usados en disfunción eréctil - alprostadil

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

recordati ireland limited - alprostadil - crema - 3 mg/g - alprostadil 3 mg - alprostadil

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

recordati ireland limited - alprostadil - excipientes: etanol anhidro,hidroxido de sodio (e-524),fosfato dihidrogeno potasico - otros productos de uso urolÓgico, incluyendo antiespasmÓdicos - fármacos usados en disfunción eréctil - alprostadil

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

recordati ireland limited - alprostadil - crema - 3 mg/g - alprostadil 3 mg - alprostadil